BACKGROUND & AIMS: Liver cancer (LC) and pancreatic cancer (PC) are often diagnosed at an advanced stage resulting in high mortality. High-quality survival data are rarely available for trend analyses over a long period. METHODS: The Danish, Finnish, Norwegian, and Swedish cancer data were accessed at the NORDCAN database. We analysed relative 1- and 5-year survival trends in LC and PC between years 1970 and 2019. RESULTS: Relative 1-year survival in LC for Nordic men and women was about 10% in the period between 1970 and 1974, and it increased moderately by year 2000 and steeply thereafter, eventually reaching 40-50%. The patterns in 5-year survival were similar, but after the year 2000, survival in Norway and Sweden increased steeply to 23%, whereas survival in Denmark and Finland lagged behind, reaching 10% to 15%. The patterns for PC also showed rapid improvement after the year 2000, with 1-year survival reaching 30% to 40% and 5-year survival reaching 10% for Finland and 15% for Norway and Sweden. Survival was best for patients diagnosed before age 50 years, and it was worst for older patients. For both cancers the difference between 1- and 5-year survival increased with time. CONCLUSIONS: Survival in LC and PC improved first modestly and then steeply over the 50-year period covered. The increase in 5-year survival was less than that of 1-year survival. The survival gains were most likely the result of earlier diagnosis, improved treatment, and better organised supportive care. The challenges are to keep up these positive trends, to extend survival benefits past Year 1, and to obtain similar results in elderly patients. Primary prevention through avoidance of risk factors would reduce case numbers. LAY SUMMARY: Liver and pancreatic cancers are among the most lethal of all cancers. In 50 years, survival in these cancers has slowly improved, and in the past 20 years, the development has been increasingly favourable. Widespread adoption of healthy lifestyles will be key to reducing the risk of these cancers.

Biomedical Center Faculty of Medicine Charles University Pilsen Czech Republic

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki Finland

Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Department of Surgery University Hospital School of Medicine in Pilsen Pilsen Czech Republic

Department of Urology Helsinki University Hospital and University of Helsinki Helsinki Finland

Division of Cancer Epidemiology German Cancer Research Center Heidelberg Germany

Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany

Hopp Children's Cancer Center Heidelberg Germany

Zobrazit více v PubMed

Arnold M., Abnet C.C., Neale R.E., Vignat J., Giovannucci E.L., McGlynn K.A., et al. Global Burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159:335–349.e15. PubMed PMC

Santucci C., Carioli G., Bertuccio P., Malvezzi M., Pastorino U., Boffetta P., et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev. 2020;29:367–381. PubMed

Arnold M., Rutherford M.J., Bardot A., Ferlay J., Andersson T.M., Myklebust T., et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–1505. PubMed PMC

Brown K.F., Rumgay H., Dunlop C., Ryan M., Quartly F., Cox A., et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer. 2018;118:1130–1141. PubMed PMC

Wilson L.F., Antonsson A., Green A.C., Jordan S.J., Kendall B.J., Nagle C.M., et al. How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013. Int J Cancer. 2018;142:691–701. PubMed

Hemminki K., Tichanek F., Försti A., Hemminki O., Liska V., Hemminki A. Long-term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast? Int J Cancer. 2022;151:510–517. PubMed

Leone V., Ali A., Weber A., Tschaharganeh D.F., Heikenwalder M. Liver inflammation and hepatobiliary cancers. Trends Cancer. 2021;7:606–623. PubMed

Li X., Ramadori P., Pfister D., Seehawer M., Zender L., Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer. 2021;21:541–557. PubMed

Nakagawa H., Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol. 2012;18:4071–4081. PubMed PMC

Mizrahi J.D., Surana R., Valle J.W., Shroff R.T. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020. PubMed

Dennaoui R., Shrestha H., Wagner K.U. Models of pancreatic ductal adenocarcinoma. Cancer Metastasis Rev. 2021;40:803–818. PubMed PMC

Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462. PubMed

Henriksson M., Björnsson B., Sternby Eilard M., Lindell G., Strömberg C., Hemmingsson O., et al. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv. BJS Open. 2020;4:109–117. PubMed PMC

Tingstedt B., Andersson B., Jönsson C., Formichov V., Bratlie S.O., Öhman M., et al. First results from the Swedish national pancreatic and periampullary cancer registry. HPB (Oxford) 2019;21:34–42. PubMed

Nymo L.S., Myklebust T., Hamre H., Møller B., Lassen K. Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort. BJS Open. 2022;6:zrac004. PubMed PMC

IARC . Cancer incidence in five Continents. IARC; Lyon: 2002.

Pukkala E., Engholm G., Hojsgaard Schmidt L.K., Storm H., Khan S., Lambe M., et al. Nordic Cancer Registries – an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–455. PubMed

Engholm G., Ferlay J., Christensen N., Bray F., Gjerstorff M.L., Klint A., et al. NORDCAN–a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49:725–736. PubMed

Rutherford M.J., Arnold M., Bardot A., Ferlay J., De P., Tervonen H., et al. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries. Int J Cancer. 2021;149:2020–2031. PubMed

Lundberg F.E., Andersson T.M., Lambe M., Engholm G., Mørch L.S., Johannesen T.B., et al. Trends in cancer survival in the Nordic countries 1990–2016: the NORDCAN survival studies. Acta Oncol. 2020;59:1266–1274. PubMed

Brenner H., Arndt V., Gefeller O., Hakulinen T. An alternative approach to age adjustment of cancer survival rates. Eur J Cancer. 2004;40:2317–2322. PubMed

Hemminki K., Försti A., Hemminki A. Survival in colon and rectal cancers in Finland and Sweden through 50 years. BMJ Open Gastroenterol. 2021;8 PubMed PMC

He C., Zhang Y., Cai Z., Lin X. Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery. BMC Cancer. 2019;19:178. PubMed PMC

Ellis L., Woods L.M., Estève J., Eloranta S., Coleman M.P., Rachet B. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014;135:1774–1782. PubMed

Lepage C., Capocaccia R., Hackl M., Lemmens V., Molina E., Pierannunzio D., et al. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999–2007: results of EUROCARE-5. Eur J Cancer. 2015;51:2169–2178. PubMed

Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Nikšić M., et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–1075. PubMed PMC

Burton A., Tataru D., Driver R.J., Bird T.G., Huws D., Wallace D., et al. Primary liver cancer in the UK: incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Rep. 2021;3 PubMed PMC

Hemminki K., Försti A., Hemminki A., Ljungberg B., Hemminki O. Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. PLoS One. 2021;16 PubMed PMC

Hemminki K., Försti A., Hemminki A., Ljungberg B., Hemminki O. Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years. PLoS One. 2022;17 PubMed PMC

Bjerregaard J.K., Mortensen M.B., Pfeiffer P., Academy of Geriatric Cancer Research (AgeCare) Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980–2012. Acta Oncol. 2016;55(Suppl. 1):40–45. PubMed

Valle J.W., Kelley R.K., Nervi B., Oh D.Y., Zhu A.X. Biliary tract cancer. Lancet. 2021;397:428–444. PubMed

Gallage S., García-Beccaria M., Szydlowska M., Rahbari M., Mohr R., Tacke F., et al. The therapeutic landscape of hepatocellular carcinoma. Med (N Y) 2021;2:505–552. PubMed

Shipley L.C., Ahmed A.M. New and emerging technology in the diagnosis and treatment of pancreatic cysts. Transl Gastroenterol Hepatol. 2022;7:15. PubMed PMC

Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594–618. PubMed

Badarna M., Percik R., Aharon-Hananel G., Uri I., Tirosh A. Anatomic site as prognostic marker of pancreatic neuroendocrine tumors: a cohort study. Eur J Endocrinol. 2019;181:325–330. PubMed

Hemminki K., Li X. Incidence trends and risk factors of carcinoid tumors a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204–2210. PubMed

Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. PubMed PMC

Klint A., Engholm G., Storm H.H., Tryggvadóttir L., Gislum M., Hakulinen T., et al. Trends in survival of patients diagnosed with cancer of the digestive organs in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:578–607. PubMed

Pijnappel E.N., Schuurman M., Wagner A.D., de Vos-Geelen J., van der Geest L.G.M., de Groot J.B., et al. Sex, gender and age differences in treatment allocation and survival of patients with metastatic pancreatic cancer: a nationwide study. Front Oncol. 2022;12 PubMed PMC

Cheng A.L., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y., et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–873. PubMed

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries

Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers

Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

Survival in Lung Cancer in the Nordic Countries Through A Half Century

Activated Hepatic Stellate Cells in Hepatocellular Carcinoma: Their Role as a Potential Target for Future Therapies